In GBM patients, the overall CD4+ T-cell numbers were decreased in both peripheral blood and the tumors compared to controls, but the fraction of T-regs within the CD4+ population was 2.63 times greater in the GBM group (18). This evidence concerns the gene CD4 and glioblastoma.